Naadira Vanker
Cape Town, WC, South Africa
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 19 publications
Accuracy of VIDASⓇ TB-IGRA in TB patients and individuals with different thresholds of exposure.
Journal: International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases
Published: August 20, 2025
High-Dose Isoniazid Lacks EARLY Bactericidal Activity against Isoniazid-resistant Tuberculosis Mediated by katG Mutations: A Randomized Phase II Clinical Trial.
Journal: American journal of respiratory and critical care medicine
Published: April 02, 2024
A Semimechanistic Model of the Bactericidal Activity of High-Dose Isoniazid against Multidrug-Resistant Tuberculosis: Results from a Randomized Clinical Trial.
Journal: American journal of respiratory and critical care medicine
Published: August 17, 2021
Mycobacteriophages to Treat Tuberculosis: Dream or Delusion?
Journal: Respiration; international review of thoracic diseases
Published: June 08, 2021
The Population Pharmacokinetics of Meropenem in Adult Patients With Rifampicin-Sensitive Pulmonary Tuberculosis.
Journal: Frontiers in pharmacology
Published: December 03, 2020
Resistance-Conferring Mycobacterial Mutations and Quantification of Early Bactericidal Activity.
Journal: American journal of respiratory and critical care medicine
Published: October 20, 2020
Fourteen-day PET/CT imaging to monitor drug combination activity in treated individuals with tuberculosis.
Journal: Science translational medicine
Published: July 10, 2020
Reply to Kim et al., "Optimal Dose or Optimal Exposure? Consideration for Linezolid in Tuberculosis Treatment".
Journal: Antimicrobial agents and chemotherapy
Published: May 06, 2020
Increased bactericidal activity but dose-limiting intolerability at 50 mg·kg-1 rifampicin.
Journal: The European respiratory journal
Published: April 10, 2020
Telacebec (Q203), a New Antituberculosis Agent.
Journal: The New England journal of medicine
Published: March 27, 2020
Reply to Decroo et al.: High-Dose First-Line Treatment Regimen for Recurrent Rifampicin-Susceptible Tuberculosis.
Journal: American journal of respiratory and critical care medicine
Published: March 05, 2020
Early Bactericidal Activity of Different Isoniazid Doses for Drug-Resistant Tuberculosis (INHindsight): A Randomized, Open-Label Clinical Trial.
Journal: American journal of respiratory and critical care medicine
Published: January 17, 2020
Last Updated: 09/26/2026